Uji klinis Obesitas di Virginia
43 studi untuk Obesitas mencari peserta di lokasi di Virginia.
Kota di Virginia
- Arlington18 studi
- Richmond11 studi
- Charlottesville8 studi
- Newport News8 studi
- Winchester5 studi
- Norfolk5 studi
- Alexandria4 studi
- Roanoke4 studi
Teks studi resmi (Bahasa Inggris)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Washington Center For Weight Management And Research /ID# 282047, Arlington
- Sovah Health - Danville /ID# 282876, Danville
- Health Research Of Hampton Roads /ID# 282014, Newport News
- dan 1 lainnya
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07752979A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Carient Heart & Vascular - Manassas, Manassas
- Carient Heart and Vascular LLC-Reston, Reston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07783802AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- National Clin Res Inc., Richmond
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07533175AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Washington Cntr Weight Mgmt, Arlington
- Health Res of Hampton Roads, Newport News
- National Clin Res Inc., Richmond
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- National Clin Res Inc., Richmond
- Gastroent Consult of SW VA, Roanoke
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- York Clinical Research, LLC, Norfolk
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Manassas
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07776509A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- VCU Health - Center for Endocrinology Diabetes and Metabolism, Richmond
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Consultants of Southwest Virginia, Roanoke
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- Washington Cntr Weight Mgmt, Arlington
- Health Res of Hampton Roads, Newport News
- Selma Medical Associates, Winchester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07339423A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Manassas
- Research Site, Norfolk
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Inova Cardiology - Fairfax, Fairfax
- Virginia Heart, Falls Church
Menerima pesertaFase 3
Usia 45 hingga 99 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Norfolk
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07321886Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Charlottesville Medical Research, Charlottesville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Sovah Clinical Research-River District, Danville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Hampton
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Hampton
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Conquest Research, LLC, Arlington
- Virginia Heart, Falls Church
- Carient Heart and Vascular, Manassas
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Manassas Clinical Research Center, Manassas
- Centricity Research Suffolk Primary Care, Suffolk
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07351058A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Burke
- ACCOMPLISH-2 Research Site, Manassas
- ACCOMPLISH-2 Research Site, Suffolk
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Selma Medical Associates, Winchester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07770841A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Sovah Clinical Research-River District, Danville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06143956A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Eastern Virginia Medical School (EVMS) Medical Group, Norfolk
- Clinical Research Partners, LLC, Richmond
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07215559A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Health Res of Hampton Roads, Newport News
- National Clin Res Inc., Richmond
- Selma Medical Associates, Winchester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07745504Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Manassas
- Kailera Clinical Site, Richmond
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Washington Center for Weight Management and Research, Inc, Arlington
- Health Research of Hampton Roads, Newport News
- Selma Medical Associates, Winchester
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Danville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Manassas Clinical Research Center Inc, Manassas
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Manassas
- Kailera Clinical Site, Richmond
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07284979A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Arlington
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- University Of Virginia Hospital, Charlottesville
- Carient Heart and Vascular, Manassas
- TPMG Clinical Research, Newport News
- dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07567001AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Health Res of Hampton Roads, Newport News
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07509307A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Charlottesville Medical Research, Charlottesville
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT07477704A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Charlottesville Med Research, Charlottesville
- Health Res of Hampton Roads, Newport News
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07481630Brief Inhibitory Training for Eating - Intervention
- George Mason University, Fairfax
Menerima peserta
Usia 14 hingga 17 · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT07592728Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- Children's Hospital of Richmond at VCU Healthy Lifestyles Center, Henrico
Menerima pesertaSukarelawan sehat diterima
Usia 4 ke atas · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT06714929Redefining BMI: The Body, Mind, and Inflammation Trial
- Virginia Commonwealth Universtity, Richmond
Menerima peserta
Usia 18 hingga 25 · Wanita · Diperbarui 6 Mei 2026 · NCT06532747A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- Vanda Investigational Site, Burke
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT07446439Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
- University of Virginia Medical Center, Charlottesville
Menerima pesertaFase 2
Usia 12 hingga 21 · Semua jenis kelamin · Diperbarui 17 Apr 2026 · NCT06903923Examining Valence-based Effects in Self-Monitoring Feedback Messages
- University of Virginia, Charlottesville
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Mar 2026 · NCT07292389Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.